Additional Therapy with Trenimon in Treatment of Carcinoma of the Uterine Cervix
The object of our studies was to investigate the additional use of cytostatic agents in primary therapy of patients with carcinoma of the uterine cervix. During the period of 1961 to 1966 a total of 146 women were treated with such agents, mostly Trenimon, in addition to the conventional basic regimen. The influence of this procedure upon the 5-year-cure-rate could be investigated.
KeywordsMatched Pair Average Dose Uterine Cervix Primary Therapy Additional Therapy
Unable to display preview. Download preview PDF.